Zura Bio Ltd
Close on Oct 19, 2026
- Market cap
- $483.12M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 11, 2026 | Before market open | – | $-0.21 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | Before market open | – | $-0.21 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | – | $-0.19 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | $-0.17 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.02 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | Before market open | – | – | – |
Press releases
Announcements Zura Bio filed with the SEC
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
7 Tibulizumab: Potential first- and only-in-class therapy Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any other regulatory agency worldwide.
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
©2026 Zura Bio Ltd. 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Overview May 2026 Nasdaq Ticker: ZURA
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Zura Bio Reports Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
©2026 Zura Bio Ltd. 2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
©2026 Zura Bio Ltd. 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Announces Proposed Public Offering
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
Zura Bio Announces Pricing of $125 Million Public
Material agreement · Results of operations · Other events · EX-99.2 to Form 8-K
Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
©2026 Zura Bio Ltd. 2
Regulation FD disclosure · EX-99.1 to Form 8-K
Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
©2026 Zura Bio Ltd. 2
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Business Updates and Outlook for 2026
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Third Quarter 2025 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Advancing Dual - Pathway Biologic Candidates in Autoimmune and Inflammatory Diseases September 2025 Nasdaq Ticker: ZURA
Regulation FD disclosure · EX-99.1 to Form 8-K
in the Cantor Fitzgerald Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Second Quarter 2025 Financial Results and
Results of operations · EX-99.1 to Form 8-K
Zura Bio Announces Chief Financial Officer Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Jefferies Global Healthcare Conference 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
at the Jefferies Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Launches Global Phase 2 TibuSHIELD
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Reports First Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
©2025 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases March 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Reports Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
at the Leerink Partners Global Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
©2025 Zura Bio Ltd. Nasdaq Ticker: ZURA Advancing Dual - Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases January 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Launches Global Phase 2 TibuSURE Study
Regulation FD disclosure · EX-99.1 to Form 8-K
at the Piper Sandler 36th Annual Healthcare Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Announces Submission of Protocol to
Regulation FD disclosure · EX-99.1 to Form 8-K
Third Quarter 2024 Financial Results and Recent Corporate Updates
Results of operations · EX-99.1 to Form 8-K
in Two Upcoming Investor Conferences in November
Regulation FD disclosure · EX-99.1 to Form 8-K
©2024 Zura Bio Ltd. 2
Regulation FD disclosure · EX-99.1 to Form 8-K
at Three Upcoming Investor Conferences in September
Regulation FD disclosure · EX-99.1 to Form 8-K
©2024 Zura Bio Ltd. Nasdaq Ticker: ZURA Three unique dual - pathway biologics, clinically validated for therapeutic areas with unmet needs August 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
Zura Bio Reports Second Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Zura Bio Completes Exchange Offer and
Material agreement · Shareholder vote results · Other events · EX-99.1 to Form 8-K